Cancer Vaccine PC: X
Russia's Entermomix cancer vaccine has shown a 100% effectiveness in preclinical trials, combining safety and strong tumour-fighting results, as per Tass reports. The breakthrough has shed a ray of hope to cancer patients across the globe.
Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), shared the findings at the Eastern Economic Forum (EEF). "The research spanned several years, with the last three dedicated to mandatory preclinical studies. The vaccine is now ready for use; we are awaiting official approval," she said.
Skvortsova highlighted that repeated doses of the vaccine were safe and highly effective. Results showed tumour growth slowing by 60-80%, improved survival rates, and a significant reduction in tumour size.
ALSO READ: 5 Overlooked Signs of Breast Cancer Beyond a Lump
The vaccine will first be used for colorectal cancer, one of the leading causes of cancer deaths worldwide. Researchers are also working on versions for glioblastoma (an aggressive brain cancer) and specific melanomas, including ocular melanoma, which are already in advanced stages of development.
While most people associate vaccines with childhood illnesses like measles or chickenpox, cancer vaccines follow a similar concept. They train the immune system not to attack viruses, but to detect and fight cancer cells.
ALSO READ: Beta-Blockers Show Promise in Treating Aggressive Breast Cancer
There are already some vaccines for bladder and prostate cancers, and the HPV vaccine prevents a number of cancers before they develop. These are different from those. Enteromix belongs to a new generation of therapeutic vaccines, which will not only treat cancer but do so by stimulating the body's own defences.
The announcement was made at the 10th Eastern Economic Foroum in Vladivostok, hosting 8,400 delegates from 75 countries. The vaccine became the highlight of the event. If approved, it will bring a major turning point in global cancer treatment.
